spanlecortemlocel

{
  "id": "MLC-T-ONC-016840",
  "term": "spanlecortemlocel",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of allogeneic umbilical cord blood (UCB)-derived hematopoietic stem and progenitor cells (HSPCs) expanded in culture with the stimulatory cytokines stem cell factor (SCF; Kit ligand; mast cell growth factor; MGF), FMS-like tyrosine kinase 3 ligand (Flt3L), interleukin 6 (IL-6), and thrombopoietin, in the presence of an aryl hydrocarbon receptor (AHR) antagonist LHD221 (StemRegenin-1; SR-1), with potential to improve hematopoietic recovery following myeloablative conditioning. Upon administration of spanlecortemlocel, these cells increase and restore the number of HSPCs, which may prevent or decrease the risk of infection and other complications of chemotherapy-induced neutropenia (CIN) or cord blood transplantation. LHD221, an AHR antagonist facilitates the expansion of CD34-positive hematopoietic progenitors and impedes HSPC differentiation during cytokine-driven expansion in culture.",
  "synonyms": [
    "expanded umbilical cord blood product HSC835",
    "allogeneic UCB-derived HSPCs MGTA 456",
    "allogeneic umbilical cord blood-derived hematopoietic stem and progenitor cells MGTA-456"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/spanlecortemlocel/"
}